van der Bruggen P - Search Results

1

Reverse immunology: From peptide sequence to tumor-killing human T-cell clones.

Vanhaver C, Gordon-Alonso M, Bayard A, Catanese MT, Colau D, van der Bruggen P, Bruger AM. Vanhaver C, et al. Among authors: van der bruggen p. Methods Enzymol. 2020;631:159-194. doi: 10.1016/bs.mie.2019.05.033. Epub 2019 Jun 17. Methods Enzymol. 2020. PMID: 31948546

2

Molecular definition of tumor antigens recognized by T lymphocytes.

van der Bruggen P, Van den Eynde B. van der Bruggen P, et al. Among authors: van den eynde b. Curr Opin Immunol. 1992 Oct;4(5):608-12. doi: 10.1016/0952-7915(92)90035-d. Curr Opin Immunol. 1992. PMID: 1418727 Review.

3

A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.

van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A, Boon T. van der Bruggen P, et al. Eur J Immunol. 1994 Dec;24(12):3038-43. doi: 10.1002/eji.1830241218. Eur J Immunol. 1994. PMID: 7805731

4

Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.

Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Chaux P, et al. Among authors: van der bruggen p. J Exp Med. 1999 Mar 1;189(5):767-78. doi: 10.1084/jem.189.5.767. J Exp Med. 1999. PMID: 10049940 Free PMC article.

5

A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes.

Luiten R, van der Bruggen P. Luiten R, et al. Among authors: van der bruggen p. Tissue Antigens. 2000 Feb;55(2):149-52. doi: 10.1034/j.1399-0039.2000.550206.x. Tissue Antigens. 2000. PMID: 10746786

6

A reversible functional defect of CD8+ T lymphocytes involving loss of tetramer labeling.

Demotte N, Colau D, Ottaviani S, Godelaine D, Van Pel A, Boon T, van der Bruggen P. Demotte N, et al. Among authors: van pel a, van der bruggen p. Eur J Immunol. 2002 Jun;32(6):1688-97. doi: 10.1002/1521-4141(200206)32:6<1688::AID-IMMU1688>3.0.CO;2-9. Eur J Immunol. 2002. PMID: 12115652 Free article.

7

Tumor-specific shared antigenic peptides recognized by human T cells.

Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T. Van Der Bruggen P, et al. Among authors: van den eynde bj. Immunol Rev. 2002 Oct;188:51-64. doi: 10.1034/j.1600-065x.2002.18806.x. Immunol Rev. 2002. PMID: 12445281 Review.

8

New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells.

Kobayashi T, Lonchay C, Colau D, Demotte N, Boon T, van der Bruggen P. Kobayashi T, et al. Among authors: van der bruggen p. Tissue Antigens. 2003 Nov;62(5):426-32. doi: 10.1034/j.1399-0039.2003.00123.x. Tissue Antigens. 2003. PMID: 14617050

9

Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.

Corbière V, Nicolay H, Russo V, Stroobant V, Brichard V, Boon T, van der Bruggen P. Corbière V, et al. Among authors: van der bruggen p. Tissue Antigens. 2004 May;63(5):453-7. doi: 10.1111/j.0001-2815.2004.00203.x. Tissue Antigens. 2004. PMID: 15104676

10

Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.

Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T. Lonchay C, et al. Among authors: van pel a, van baren n, van der bruggen p. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2(Suppl 2):14631-8. doi: 10.1073/pnas.0405743101. Epub 2004 Sep 27. Proc Natl Acad Sci U S A. 2004. PMID: 15452345 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

139 results

Search Page